CytoCore Inc., a leading developer of extremely accurate, cost-effective and easily deployable early-warning cytology screening systems, with specific emphasis on gynecological cancers like cervical or endometrial, today announced the retention of Dr. Mauro Scimia to head up the Company’s European marketing and sales division.
CEO of CYOE, Robert McCullough Jr., pointed to the outstanding track record of successes in “cervical cytology screening and molecular testing sales combined with his focus on execution and strong management skills” as contributing to his appointment to this position.
A 15-year veteran, leading sales, marketing and management concerns with such industry powerhouses as Cytec – Hologic, Third Wave Technology (now owned by Hologic) and NeuroMedical Systems (which was bought by Tripath, which is now a business segment of Becton Dickinson), Dr. Scimia and his team already have a significant amount of time in the field, spearheading product roll-outs in European markets.
Dr. Scimia expressed his enthusiasm over the appointment by stating his eagerness to work with CYOE in order to build what he called a “best-in-class sales organization”, as they collectively worked towards greater overall market penetration in cytology.
With the ability to revolutionize cytology cancer screening and diagnostic capabilities industry-wide, CytoCore Solutions can save many lives by aiding in the detection of precancerous and cancerous conditions at a time when they can be readily treated.
The CYOE “SoftPAP Kit”, consisting of a collection device and preservative medium for storing samples, offers a new compliance benchmark by streamlining both PAP and HPV sample collections for the testing of cervical cancer, which is a leading cause of fatalities among women the world over.
The concept of incorporating the sample storage medium and collector into one kit is the first to market and offers European customers a competitively priced and technologically innovative product which, with the help of the good doctor, should almost sell itself.